Table 2 Bias risk assessment of the trials with reference to the Cochrane Collaboration.

From: Long-term (2–5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis

Trials

A

B

C

D

E

F

G

Total score

Bias grade

ENDEAVOR III

2

1

2

1

2

1

1

10

B

ENDEAVOR IV

2

1

1

1

2

1

1

9

B

ISAR TEST 2

2

2

2

1

2

1

1

11

A

PRODIGY

2

1

1

1

2

1

1

9

B

PROTECT

2

2

2

2

2

1

1

12

A

SORT OUT III

2

2

1

2

2

1

1

11

A

ZEST

2

2

1

1

2

1

1

10

B

PRISON III

2

2

2

1

2

1

1

11

A

ZOMAxx I

2

2

2

2

2

1

1

12

A

RESOLUTE

2

2

2

1

2

1

1

11

A

TWENTE

2

1

1

1

2

1

1

9

B

TWENTE II

2

2

2

1

2

1

1

11

A

  1. The seven components recommended by the Cochrane Collaborations to assess bias risk: A: Sequence generation B: Allocation sequence concealment C: Blinding of participants and personnel D: Blinding of outcome assessment E: Incomplete outcome data F: Selective outcome reporting G: Other potential sources of bias.
Back to article page